Form 4: Verastem CFO Daniel Calkins Reports Stock Transactions Following FDA Approval

Daniel Calkins, CFO of Verastem, Inc., reports acquisition and disposal of company stock following the FDA approval of the company's combination therapy.

Summary

• On May 16, 2025, Daniel Calkins, CFO of Verastem, Inc., acquired 38,850 shares of common stock at $0.00 per share due to the vesting of a performance RSU award.
• The vesting was triggered by the FDA approval of Verastem's combination therapy for low-grade serous ovarian cancer.
• On May 20, 2025, Calkins sold 11,143 shares at $8.13 per share to cover statutory withholding requirements related to the vesting of restricted stock units.
• Following these transactions, Calkins directly owns 114,055 shares of Verastem common stock.

Sentiment

Score: 7

Explanation: The document reflects a positive event (FDA approval) triggering stock transactions, but also includes a sale of shares to cover tax obligations, resulting in a moderately positive sentiment.

Positives

• The vesting of the performance RSU award indicates the achievement of a significant milestone for Verastem, specifically FDA approval of their combination therapy.
• The CFO's continued direct ownership of 114,055 shares suggests confidence in the company's future prospects.

Industry Context

FDA approval of a new cancer therapy is a significant event in the pharmaceutical industry, often leading to increased investor interest and potential market growth for the company.

Comparison to Industry Standards

• Executive stock transactions are common after major company events like FDA approvals.
• The sale of shares to cover tax obligations is a standard practice among executives receiving stock-based compensation.
• Comparing Verastem's stock performance and executive compensation structure to similar biotech companies that have recently received FDA approval would provide further context.

Stakeholder Impact

• Shareholders may view the FDA approval and subsequent stock transactions as a positive sign for the company's future.
• Employees may be motivated by the company's success in achieving FDA approval.
• Patients with low-grade serous ovarian cancer may benefit from the newly approved therapy.

Key Dates

Keywords

Verastem, Daniel Calkins, CFO, Stock Transactions, FDA Approval, RSU, VSTM, Beneficial Ownership